ArticleVeterinary ophthalmology2011
Mitomycin C: a promising agent for the treatment of canine corneal scarring.
Article in Veterinary ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Inhibiting Postoperative Fibrosis in Glaucoma Filtration Surgery Through Porous PLLA/RGD Membrane Mediated Local/Sustained Delivery of Mitomycin C.Translational vision science & technology · 2025Article
- Impact of keratocyte differentiation on corneal opacity resolution and visual function recovery in male rats.Nature communications · 2024Article
- Evaluation of a novel combination of TRAM-34 and ascorbic acid for the treatment of corneal fibrosis in vivo.PloS one · 2022Article
- Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis.Frontiers in pharmacology · 2022Article
- Glutathione is a potential therapeutic target for acrolein toxicity in the cornea.Toxicology letters · 2021Article
- Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.Scientific reports · 2021Article
- Comparative evaluation of decellularized bovine omentum alone and in combination with mitomycin-C in the management of corneal injuries in dogs.Veterinary world · 2020Article
- Effect of revision dacryocystorhinostomy under nasal endoscopy on recrudescent dacryocystitis.International journal of clinical and experimental pathology · 2017Article
- Effect of onion extract on corneal haze suppression after air assisted lamellar keratectomy.The Journal of veterinary medical science · 2016Article
- Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn.Frontiers in pharmacology · 2016Article
- Therapeutic potential of Pirfenidone for treating equine corneal scarring.Veterinary ophthalmology · 2015Article
- Evaluation of an injectable thermosensitive hydrogel as drug delivery implant for ocular glaucoma surgery.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveTo evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.
methodsWith an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum-free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase-contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real-time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.
resultsA single 2-min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α-smooth muscle actin and F-actin).
conclusionThis in vitro study suggests that a single 2-min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.